Chemically Defined Culture Medium for Haemophilus influenzae Type b Antigen Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for producing capsular polysaccharides of Haemophilus influenzae type b on an industrial scale face variability due to batch differences in culture media composition, leading to inconsistent antigen yields and increased production of contaminant lipopolysaccharides, which complicates vaccine production and requires frequent process modifications.
Innovation Solution
A chemically defined culture medium devoid of complex nitrogen or carbon sources, containing specific carbon sources, protoporphyrin, salts, amino acids, NAD, vitamins, and pH-regulating components, is used to culture Haemophilus influenzae type b, optimizing capsular polysaccharide production while minimizing biomass and lipopolysaccharide production, and the polysaccharide is conjugated to a carrier protein for vaccine preparation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If plant peptones are used to replace animal peptones in the culture medium, then the safety of pharmaceutical products is improved by eliminating the risk of transmission of diseases such as bovine spongiform encephalitis, but the consistency of production is worsened due to batch variations in peptone composition leading to variations in bacterial amounts and antigen yields
Solution Approach 1:
The patent transitions from using complex peptone sources (animal or plant) to a chemically defined medium with precise parameter control. The medium composition is standardized with specific concentrations of carbon sources, nitrogen sources, vitamins, and minerals, eliminating batch variations inherent in natural peptones while maintaining safety by avoiding animal products.
Solution Approach 2:
The patent creates a simplified model system that copies the essential nutritional requirements of Haemophilus influenzae without relying on complex natural peptones. The chemically defined medium replicates the functional role of peptones (providing carbon, nitrogen, and growth factors) through individually controlled chemical components, ensuring reproducibility.
2Productivity
If the amount of bacteria is increased to improve antigen production, then the antigen yield is improved, but the amount of lipopolysaccharides produced increases proportionally, complicating purification
Solution Approach 1:
The patent optimizes culture parameters including pH regulation, temperature control, and carbon-to-nitrogen ratio to shift bacterial metabolism toward capsular polysaccharide production. The chemically defined medium with controlled amino acid composition prevents excessive biomass accumulation while maximizing PRP synthesis, thereby improving antigen yield without proportional increase in LPS.
Solution Approach 2:
The patent selectively extracts and utilizes only the necessary nutritional components for capsular polysaccharide synthesis from the culture medium, while minimizing the production of unwanted by-products like LPS. The controlled medium composition allows selective extraction of PRP during purification without co-extraction of excessive LPS.
3Productivity
If complex sources of nitrogen or carbon are used in the culture medium, then the growth of bacteria is improved, but the purification of capsular polysaccharide is complicated due to the presence of proteins and other contaminants
Solution Approach 1:
The patent removes complex protein-containing nitrogen sources (peptones, casein) from the culture medium and replaces them with defined chemical nitrogen sources (ammonium salts, urea, or specific amino acids). This extraction of complexity from the medium composition enables simpler purification of capsular polysaccharide by reducing the spectrum of contaminants while maintaining adequate bacterial growth.
Solution Approach 2:
The patent transforms the culture medium from a complex composition with variable composition to a chemically defined system with fixed parameters. This parameter control ensures consistent bacterial growth while producing a more predictable profile of cellular components, thereby simplifying the purification process and reducing the number of purification steps required.
Data Source
AI summary
The invention concerns a method for producing, on an industrial scale, capsular polysaccharide of Haemophilus influenzae type b (PRP) intended for vaccine purposes, according to which a strain of Haemophilus influenzae type b (Hib) is cultured in a culture medium, the culture supernatant is harvested and treated in order to extract the capsular polysaccharide therefrom, said culture medium comprising at least: —one source of carbon, —protoporphyrin, —salts, —amino acids, —NAD or NADH, —vitamins, —means for regulating the pH, characterized in that said culture medium is chemically defined.